Syntara (ASX:SNT) Cash Flow from Others : A$-0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Cash Flow from Others?

Syntara's cash flow from others for the six months ended in Dec. 2023 was A$-0.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.00 Mil.

Syntara Cash Flow from Others Historical Data

The historical data trend for Syntara's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Cash Flow from Others Chart

Syntara Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash Flow from Others

Get a 7-Day Free Trial

Syntara Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash Flow from Others	Get a 7-Day Free Trial															-	-	-	-	-

Syntara Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00 Mil.

Syntara Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Syntara's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.